Report Published: "PharmaPoint: Insomnia - Global Drug Forecast and Market Analysis to 2023"

Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo's Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.

Full Report Details at
- http://www.fastmr.com/prod/998609_pharmapoint_insomnia_global.aspx?afid=301

Highlights

Key Questions Answered

* The insomnia market is dominated by the generic nonbenzodiazepines and low-does sedating antidepressants. Novel products have not had a significant impact on this market as they lack notable clinical advantages over the current first-line drugs. What are the unmet needs in light of this? Will there be opportunities in this market for drug developers throughout the forecast period?
* The current late stage insomnia pipeline is sparse with only one drug having advanced to Phase III. However, GlobalData believes two orexin receptor antagonists will enter the market during the forecast period. What impact will these drugs have on the market? How will they affect the treatment algorithm for insomnia? Will these drugs fulfil any of the unmet needs for insomnia?
* Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of insomnia. How will epidemiological changes impact the growth of the future insomnia market?

Key Findings

* The main driver of growth in the insomnia market will be the introduction of the orexin receptor antagonists over the forecast period. The launch of this novel drug class may address some of the unmet need in the insomnia market due to the safety profile of these drugs and the availability of long-term clinical trial data.
* The generic erosion of Lunesta within the insomnia market will lead to a decline in market size prior to the entry of pipeline products. The availability of generic eszopiclone could greatly affect the treatment algorithm and will put downward pricing pressure on the controlled-release zolpidem generics.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023
- PharmaPoint: HER2-Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2023